Reduction in baroreceptor reflex response by angiotension III and its modification by Ile7-angiotensin III and bestatin in the rat

Central antihypertensive effects of chronic treatment with RB150: an orally active aminopeptidase A inhibitor in deoxycorticosterone acetate-salt rats

BACKGROUND AND OBJECTIVE

Hyperactivity of the brain renin-angiotensin (Ang) system has been implicated in the development and maintenance of hypertension. AngIII, one of the main effector peptides of the brain renin-Ang system, exerts a tonic stimulatory control over blood pressure (BP) in hypertensive rats. Aminopeptidase A (APA), the enzyme generating brain AngIII, represents a new therapeutic target for the treatment of hypertension. We developed RB150, a prodrug of the specific and selective APA inhibitor, EC33. When given orally in acute treatment in hypertensive rats, RB150 crosses the gastrointestinal and blood-brain barriers, enters the brain, inhibits brain APA activity and decreases BP. We investigate, here, the antihypertensive effects of chronic oral RB150 (50 mg/kg per day) treatment over 24 days in alert hypertensive deoxycorticosterone acetate-salt rats.

METHODS

We measured variations in Brain APA enzymatic activity, SBP, plasma arginine vasopressin levels and metabolic parameters after RB150 chronic administration.

RESULTS

This resulted in a significant decrease in SBP over the 24-day treatment period showing that no tolerance to the antihypertensive RB150 effect was observed throughout the treatment period. Chronic RB150 treatment also significantly decreased plasma arginine vasopressin levels and increased diuresis, which participate to BP decrease by reducing the size of fluid compartment. Interestingly, we observed an increased natriuresis without modifying both plasma sodium and potassium levels.

CONCLUSION

Our results strengthen the interest of developing RB150 as a novel central-acting antihypertensive agent and evaluating its efficacy in salt-sensitive hypertension.

Tonic suppression of spontaneous baroreceptor reflex by endogenous angiotensins via AT(2) subtype receptors at nucleus reticularis ventrolateralis in the rat

We evaluated the role of endogenous angiotensins at the rostral nucleus reticularis ventrolateralis (NRVL) in the modulation of spontaneous baroreceptor reflex (BRR) response and the subtype of angiotensin receptors involved using rats anesthetized and maintained with pentobarbital sodium. Bilateral microinjection of angiotensin II (ANG II) or its active metabolite angiotensin III (ANG III) (5, 10, or 20 pmol) into the NRVL significantly suppressed the spontaneous BRR response, as represented by the magnitude of transfer function between systemic arterial pressure and heart rate signals. The inhibitory effect of ANG III (20 pmol) was discernibly reversed by coadministration with its peptide antagonist, [Ile(7)]ANG III (1.6 nmol), or the nonpeptide AT(2) receptor antagonist, PD-123319 (1.6 nmol), but not by the nonpeptide AT(1) receptor antagonist, losartan (1.6 nmol). On the other hand, the peptide antagonist, [Sar(1), Ile(8)]ANG II (1.6 nmol) or both non-peptide antagonists appreciably reversed the suppressive action of ANG II (20 pmol). Whereas losartan produced minimal effect, blocking the endogenous activity of the angiotensins by microinjection into the bilateral NRVL of PD-123319, [Sar(1), Ile(8)]ANG II or [Ile(7)]ANG III elicited significant enhancement of the spontaneous BRR response. We conclude that under physiologic conditions both endogenous ANG II and ANG III may exert a tonic inhibitory modulation on the spontaneous BRR response by acting selectively on the AT(2) subtype receptors at the NRVL.

Pressor and renal effects of intracerebroventricularly administered angiotensins II and III in rats

AIMS

Experiments were performed to assess the effects of intracerebroventricular (ICV) angiotensin (ANG) III on blood pressure and renal function in rats with normal and high sodium intake and to compare these effects with those produced by ICV ANG II.

METHODS

Male Sprague-Dawley rats on a normal sodium (0.3%) diet and a normal sodium diet plus 1% NaCl as drinking water were administered ANG II and ANG III ICV through a chronically implanted cannula. Blood pressure and renal clearance function responses were measured before and during peptide administrations. The effect of ICV ANG III on the renal efferent nerve activity was also evaluated.

RESULTS

ICV injections of ANG II and ANG III at 5 pmol in rats on a normal sodium diet did not significantly alter the blood pressure, but significantly increased renal plasma flow, glomerular filtration rate, urine flow, and absolute and fractional excretions of sodium and potassium. Increased doses of ANG II and III (10, 50 and 100 pmol) significantly increased blood pressure and further enhanced these renal functional indices. Central ANG-III-induced increases in blood pressure and renal functional indices were not significantly different from those produced by ANG II at each corresponding dose. The pressor and renal effects of ANG III were blunted by a specific antagonist, Ile(7)-ANG III. ICV administration of ANG III decreased the renal efferent nerve activity. In rats with dietary NaCl loading, ICV injections of ANG II and III also significantly enhanced renal function.

CONCLUSIONS

Centrally administered ANG III is as potent as ANG II in causing pressor and renal effects in rats on normal and high sodium intake. As ANG II, brain ANG III reduced renal efferent nerve activity which may be partly accounted for the augmented renal function.

Participation of AT1 and AT2 receptor subtypes in the tonic inhibitory modulation of baroreceptor reflex response by endogenous angiotensins at the nucleus tractus solitarii in the rat

We evaluated the endogenous action of angiotensin II (AII) and its active metabolite, angiotensin III (AIII), at the nucleus tractus solitarii (NTS) in the modulation of baroreceptor reflex (BRR) response, and the subtype(s) of angiotensin receptors involved in this process. Adult, male Sprague-Dawley rats that were anesthetized and maintained with pentobarbital sodium were used. Bilateral microinjection of AII or AIII (10, 20 or 40 pmol) into the NTS significantly and dose-dependently suppressed the BRR response, which was evoked by transient hypertension induced by phenylephrine (5 micrograms/kg, i.v.). The suppressive effect of AII (40 pmol) was reversed by co-administration of the non-peptide AT1 receptor antagonist, losartan (1.6 nmol), but only partially by the non-peptide AT2 receptor antagonist, PD-123319. On the other hand, both angiotensin receptor antagonists appreciably reversed the depressive action of AIII (40 pmol). Blocking the endogenous activity of the angiotensins by microinjection into the bilateral NTS of losartan (1.6 nmol) or PD-123319 (1.6 nmol) elicited a significant enhancement of the BRR response. An interruption of the conversion of AII to AIII with the aminopeptidase A inhibitor, amastatin (3.3 nmol), attenuated, but did not eliminate, the AII-induced inhibition of the BRR response. We conclude that whereas the endogenous AIII may exert a tonic inhibitory modulation on the BRR response by acting on both the AT1 and AT2 receptor subtypes, the same action of the endogenous AII engaged only the AT1 receptor subtype at the NTS. Furthermore, at least part of the suppressive action of AII may result from its metabolic conversion to AIII.

Physiological Role of Brain Angiotensin III in Drinking Behavior in the Rat

We examined the physiologic role of endogenous brain angiotensin III (AIII), an active degradative product of angiotensin II, in drinking behavior. Adult, male spontaneously hypertensive (SH) and Wistar-Kyoto normotensive (WKY) rats that were instrumented with an intracerebroventricular (i.c.v.) cannula connected to an osmotic minipump for chronic infusion were used. 7-day i.c.v. infusion of the specific AIII antagonist, Ile(7)-AIII (10 or 100 pmol/min), resulted in no significant alteration in daily (24 h), diurnal (8:00 a.m.-8.00 p.m.) or nocturnal (8:00 p.m.-8:00 a.m.) basal water intake in both SH and WKY rats. Similar results were obtained with i.c.v. infusion of the aminopeptidase inhibitor, bestatin (150 or 300 pmol/min), given alone or simultaneously with Ile(7)-AIII (10 pmol/min). Rats that were water-deprived for the first 3 days of 7-day infusion of Ile(7)-AIII consumed significantly less water during the first 2 h after water became available. Furthermore, the accumulated water intake during the first 24 h was appreciably greater in SH than WKY rats. We interpret these results to suggest that the endogenous brain AIII may not be tonically involved in fluid homeostasis. Instead, it must be activated under conditions of dehydration, such as water deprivation, particularly in the SHRs, to initiate drinking behavior. Copyright 1996 S. Karger AG, Basel

Intracerebroventricular administration of angiotensin II increases heart rate in the conscious trout

The central effect of angiotensin II on cardiovascular activity has been investigated in conscious trout bearing an intracerebroventricular (i.c.v.) cannula and an intra-arterial catheter. I.c.v. injection of the angiotensin II agonist [Asn1,Val5]AII (6.2-50 pmol) induced a dose-dependent increase in heart rate and arterial blood pressure. Central administration of the angiotensin II antagonist DuP 753 (5 nmol) 30 min before i.c.v. injection of [Asn1,Val5]AII totally prevented the tachycardia and reduced the hypertension induced by the angiotensin II agonist. Intra-arterial injection of arginine-vasotocin (12.5 pmol) caused a bradycardia associated with a marked increase in arterial blood pressure. I.c.v. injection of [Asn1,Val5]AII totally blocked the bradycardia induced by arginine-vasotocin and this effect was prevented by central administration of DuP 753. In contrast, [Asn1,Val5]AII did not affect the increase in blood pressure induced by arginine vasotocin. Suppression of the vagal tone by atropine treatment totally blocked the central effect of [Asn1,Val5]AII. These results show that angiotensin II acts directly on the trout brain to increase blood pressure and heart rate. The effect of angiotensin II is mediated through a receptor related to the mammalian AT1 receptor type.

Characterization and application of microdialysis probes with an active exchange length compatible with small-size brain nuclei in the rat

We communicated the construction, characterization and application of microdialysis probes with an active exchange length that is suitable for experiments involving small-size nuclei in rat brain. Using substance P (SP) as the test substance, we determined that probes with an active exchange length of 180-200 microns exhibited an in vitro recovery of 14.2 +/- 0.8% and in vivo recovery at the nucleus tractus solitarii (NTS) of 24.9 +/- 1.7% for the undecapeptide, calibrated at an infusion rate of 1 microliter/min. We also demonstrated that microinfusion of SP via these probes into the NTS allowed for a correlation of changes in tissue levels of both SP (exogenous substance) and norepinephrine (endogenous substance) with alterations in baroreceptor reflex responses (physiologic phenomenon).

Modulation by angiotensin III of nociception-related and arterial pressure-related neuronal responsiveness in the nucleus reticularis gigantocellularis of the rat

We evaluated possible modulation by angiotensin III (AIII) of the interactive effect of noxious stimuli and elevation in systemic arterial pressure on the responsiveness of neurons in the nucleus reticularis gigantocellularis (NRGC) of the medulla oblongata. Combined extracellular single-neuron recording and microiontophoresis were carried out on male, adult Sprague-Dawley rats anesthetized with pentobarbital sodium. The responsiveness of NRGC neurons to nociception (tail clamp) and/or transient hypertension elicited by phenylephrine (5 micrograms/kg, i.v.), in the absence or presence of AIII, was used as the experimental index. Microiontophoretic application of the heptapeptide suppressed the responses of spontaneously active NRGC neurons to individually delivered nociception or hypertension. Interestingly, the preferential reduction in responsiveness to tail clamp upon simultaneous elevation in arterial pressure was reversed to one that favored nociception in the presence of AIII. These actions of the heptapeptide appeared to be receptor-specific, since they were discernibly blocked by its selective antagonist, Ile7-angiotensin III. Our results reveal that neuropeptides such as AIII may differentially modulate neuronal responsiveness according to the prevailing physiologic input(s) to the central nervous system of the animal.

Effects of central angiotensin II and angiotensin III on baroreflex regulation

In the present study the cardiovascular effects of intracerebroventricularly (i.c.v.) applied angiotensin II (AN II) and angiotensin III (AN III) were analysed in conscious Wistar rats. The baroreceptor heart reflex (BHR) was elicited by intravenous bolus injection of both phenylephrine (1 microgram) and sodium nitroprusside (5 micrograms) before and after i.c.v. administration (1.5 and 15 min) of the peptides. Administration of 20 ng and 200 ng AN II produced a short increase in inter-beat interval (IBI) and a long-lasting increase in mean blood pressure (MBP), inclusive of a drinking response. Only after the high dose of 200 ng AN II we found a continuous impairment in the BHR for reflex bradycardia. Inversely, the small doses of both 100 pg AN II and 100 pg AN III were without effects on IBI and MBP; they induced an enhancement in BHR for the reflex bradycardia and after 100 pg AN II it was also found for the reflex tachycardia. Pretreatment with 20 nmol amastatin (AM), a specified aminopeptidase A inhibitor, followed by 100 pg An II suppressed the enhancement in BHR. AM alone was without effects in this respect. These findings suggest that: 1) the influence of central angiotensin on the BHR could be dose-dependent in the opposite way and 2) AN III seems to be the active form and involved in the central blood pressure regulatory mechanism.

Sheep hypothalamus contains a non-angiotensin ligand for type 1 and type 2 angiotensin II receptors

1. The aim of this study was to determine whether the brain contains an alternative ligand for angiotensin II (AII) receptors. 2. A radioreceptor assay based upon bovine cerebellar membranes (Type 2 AII receptors) was used to monitor the partial purification of an AII-like material from sheep hypothalami. 3. This material displaces 125I-[Sar1, Ala8]-AII from both type 1 (rat adrenal capsular membranes) and Type 2 AII receptors in a manner parallel to that of AII. It has a size of approximately 30,000 Da, is strongly cationic, is stable to boiling but is destroyed by trypsin. It is not recognized by AII antisera. 4. These data provide direct evidence for a non-angiotensin endogenous ligand for brain AII receptors. This novel ligand may play a role in the regulation of blood pressure and other actions mediated by brain AII receptors.

The renin-angiotensin system in the brain: an update 1993

The renin-angiotensin system is considered to be one of the most important hormonal systems in the regulation of blood pressure and body fluid homeostasis. Ever since this system has been demonstrated to be present also in the brain, vast efforts have been made in investigating its central impact and function. The last few years, and especially the development of non-peptidic angiotensin II receptor subtype specific antagonists and the subsequent pharmacological characterization of these subtypes, brought this field of research a large step forward. This progress also might have opened up new avenues of developing highly specific anti-hypertensive drugs and thereby new ways of treating hypertension. This paper intends to provide a summary of the knowledge about the brain renin-angiotensin system accumulated during recent years; an update 1993.

Inhibition by locus coeruleus on the baroreceptor reflex response in the rat

We evaluated the modulation of baroreceptor reflex (BRR) response by locus coeruleus (LC) in adult, male Sprague-Dawley rats anesthetized with urethane (1.5 g/kg, i.p.). Under an electrical stimulation condition that did not appreciably alter the basal systemic arterial pressure and heart rate, the LC significantly suppressed the BRR response. Microinjection of L-glutamate (1 nmol, 50 nl) into the LC essentially duplicated this depressant effect. Intracerebroventricular (i.c.v.) administration of the alpha 1-adrenoceptor antagonist, prazosin (6.5 nmol), appreciably blunted the inhibition by LC on the BRR response. Yohimbine (6.5 nmol), the alpha 2-adrenoceptor blocker, however, was ineffective. Direct microinjection of prazosin (50 pmol), but not yohimbine (50 pmol), into the terminal site of baroreceptor afferents at the nucleus tractus solitarii (NTS) also significantly blunted the suppressive effect of LC on the BRR response. These results suggest that the LC may produce an inhibition on the BRR response by a process that involves the alpha 1-adrenoceptors located in the NTS.

Enhanced renal response to intracerebroventricular angiotensins II and III in spontaneously hypertensive rats

The acute effects of intracerebroventricular (i.c.v.) administration of angiotensin III (ANG III) on blood pressure (BP) and renal function were investigated in spontaneously hypertensive rats (SHR, n = 31) and Wistar-Kyoto (WKY) normotensive rats (n = 6). ANG II was also administered to the same rats for comparison of its renal effect. BP and renal clearance responses were measured before and during ANG injections. The results showed that i.c.v. injections of 1, 5 and 50 pmol of ANG III did not significantly alter BP in SHR, but a high dose of ANG III (50 pmol) caused a vasopressor effect (7 +/- 4 mmHg) in WKY rats. There were significant increases in renal plasma flow (RPF), glomerular filtration rate (GFR), urine flow, absolute and fractional excretions of sodium and potassium, osmolar clearance and free water reabsorption rate following i.c.v. administration of ANG III in both SHR and WKY rats. However, the enhancement in renal responsiveness to ANG III was greater in SHR than in the WKY group. At 5 pmol of ANG III, the peak increases in GFR (96 +/- 23%), diuresis (316 +/- 102%) and natriuresis (712 +/- 281%) in SHR were significantly greater than those in WKY rats (40 +/- 13%, 152 +/- 89%, 229 +/- 130%, resp.). The renal effect of central ANG III was blocked by i.c.v. ANG III antagonist, [Ile7]-ANG III, but was enhanced by bestatin, an ANG III metabolic enzyme inhibitor. I.c.v. administration of ANG II at 50 pmol increased BP in both SHR and WKY rats (14 +/- 3 and 10 +/- 3 mmHg, resp.). Greater diuretic and natriuretic responses to ANG II were also noted in SHR than in WKY rats. These results indicate that central ANG III is as active as ANG II in modulating renal function. Furthermore, the enhanced renal response to i.c.v. ANGs II and III in SHR suggests a hyperactive central RAS implicated in BP and body fluid regulation in this genetic hypertensive strain.

Participation of pertussis toxin-sensitive GTP-binding regulatory proteins in the suppression of baroreceptor reflex by neurotensin in the rat

We evaluated the molecular mechanism that may underlie the suppressive effect of neurotensin (NT) on the baroreceptor reflex (BRR), using Sprague-Dawley rats that were anesthetized with sodium pentobarbital (50 mg/kg, i.p.). Intracerebroventricular (i.c.v.) application of NT (15 nmol) significantly inhibited the BRR response. Such an inhibition was appreciably antagonized by pretreating animals with i.c.v. injection of pertussis toxin (10 or 20 pmol), N-ethylmaleimide (1 or 2 nmol), forskolin (30 or 60 nmol) or phorbol 12-myristate 13-acetate (2 or 4 nmol), but not by cholera toxin (15 or 30 pmol). More specifically, pretreatments with bilateral microinjection into the nucleus tractus solitarius (NTS) of pertussis toxin (80 or 160 fmol), N-ethylmaleimide (80 pmol), forskolin (480 pmol) or phorbol 12-myristate 13-acetate (16 or 32 pmol) also blunted the NT-induced suppression of BRR, although cholera toxin (120 or 240 fmol), or 1,9-dideoxyforskolin (480 pmol) had no appreciable effect. These results suggest that a pertussis toxin-sensitive guanine nucleotide-binding regulatory protein(s), which is not likely to be Gs, possibly Gi or Gp, may be involved in the transmembrane signaling process that underlies the suppression of BRR response by NT at the NTS.

Reversal by pertussis toxin and N-ethylmaleimide of the facilitation of baroreceptor reflex response by somatostatin in the rat

We evaluated the transmembrane signaling mechanism that may underlie the facilitatory action of somatostatin (SOM) on baroreceptor reflex (BRR), using adult, male, Sprague-Dawley rats anesthetized with pentobarbital sodium (40 mg/kg, i.p.). Intracerebroventricular (i.c.v.) application of SOM (2 nmol) promoted a significant elevation in BRR response, induced by phenylephrine (5 micrograms/kg, i.v.). This potentiatory action of the tetradecapeptide was significantly reversed after pretreating animals with bilateral microinjection of pertussis toxin (25 ng) or N-ethylmaleimide (2 nmol) into the nucleus tractus solitarius (NTS), the terminal site for baroreceptor afferents. These results suggest that a pertussis toxin-sensitive GTP-binding regulatory protein, possibly Gi, may be involved in the modulation of the BRR by SOM at the NTS.

Facilitation of baroreceptor reflex response by endogenous somatostatin in the rat

We evaluated the potential participation of endogenous brain somatostatin-14 (SOM) in central cardiovascular regulation, using adult male Sprague-Dawley rats anesthetized with pentobarbital sodium (40 mg/kg, i.p.). Intracerebroventricular (i.c.v.) application of SOM (2 or 4 nmol) promoted a significant elevation in baroreceptor reflex (BRR) response, induced by phenylephrine (5 micrograms kg, i.v.). Blocking the endogenous SOM activity with its specific receptor antagonist, cyclo-[7-aminoheptanoyl-Phe-D-Trp-Lys-Thr(Bzl)] (2 or 4 nmol, i.c.v.) or antiserum against SOM (1:20, i.c.v.), on the other hand, appreciably attenuated the same response. These modulatory effects on the BRR response were essentially duplicated upon bilateral microinjections of SOM (320 pmol), SOM antagonist (320 pmol) or anti-SOM (1:20) into the caudal portion of the nucleus of tractus solitarius (NTS), the terminal site for baroreceptor afferents. These results suggest that neurons that contain SOM may participate in cardiovascular control by tonically facilitating the BRR, possibly by exerting an influence on the neurons at the NTS.

Tonic enhancement of the sensitivity of baroreceptor reflex response by endogenous substance P in the rat

Modulation of baroreceptor reflex (BRR) by endogenous substance P (SP) in the brain was investigated in rats anesthetized with pentobarbital sodium. Intracerebroventricular administration of the undecapeptide (15 or 30 nmol) and its antagonist, (D-Pro2, D-Trp7,9)-SP (30 or 60 nmol) or SP antiserum (1:20), respectively, promoted a significant increase and decrease in the sensitivity of BRR response. Prolonging the endogenous activity of SP with the aminopeptidase blocker, bestatin (200 nmol) or with the endopeptidase-24.11 inhibitor, phosphoramidon (200 nmol) significantly augmented the same reflex. Combining the undecapeptide with either peptidase blocker, moreover, promoted additional potentiation of the BRR response. On the other hand, simultaneous administration of bestatin and (D-Pro2, D-Trp7,9)-SP produced a reduction of the augmented effect of bestatin on the sensitivity of BRR response. Bilateral microinjection of SP (600 pmol) or an antiserum against SP (1:20) into the nucleus tractus solitarius (NTS) elicited respectively an enhancement of and reduction in the BRR response. These data suggest that neurons that contain SP may participate in central cardiovascular control by tonically enhancing the sensitivity of the BRR response, possibly via an action on the NTS.

Interaction between angiotensin III and alpha 2-adrenoceptors of the medulla oblongata involved in cardiovascular regulation in the rat

We evaluated, in adult, male Sprague-Dawley rats anesthetized with pentobarbital sodium, possible interaction between angiotensin III (AIII) and the alpha 2-adrenoceptors in the medulla oblongata that are involved in cardiovascular regulation. The hypotensive and negative chronotropic and inotropic actions of the alpha 2-adrenoceptor agonist, guanabenz, were used as our experimental index. Intracerebroventricular (i.c.v.) administration of AIII (100 or 200 pmol) significantly attenuated the cardiovascular suppressive effects of the aminoguanidine compound (25 or 50 micrograms/kg, i.v.). Bilateral microinjection of AIII (20 or 40 pmol) to the nucleus reticularis gigantocellularis (NRGC), a medullary site believed to be intimately related to the antihypertensive action of guanabenz, produced similar results. In addition, i.c.v. administered AIII (200 pmol) altered the effects of guanabenz on the arterial pressure-related neurons in the NRGC, in a manner that paralleled the blunted vasodepressive action of the aminoguanidine compound by the heptapeptide. When applied microiontophoretically, AIII also significantly decreased the responsiveness of arterial pressure-related neurons in the NRGC to guanabenz. These findings suggest that AIII may interact with the alpha 2-adrenoceptors located in the NRGC that are involved in central cardiovascular regulation.

Tonic suppression of baroreceptor reflex by endogenous neurotensin in the rat

We evaluated the modulatory role of endogenous neurotensin (NT) in baroreceptor reflex (BRR) response in Sprague-Dawley rats anesthetized with pentobarbital sodium. Intracerebroventricular (i.c.v.) administration of NT (15 or 30 nmol) significantly reduced the sensitivity of the BRR response. Blocking the endogenous activity of the tridecapeptide with its specific antagonist, (D-Trp11)-NT (4 or 8 nmol) or antiserum against NT (1:20); or inhibiting the aminopeptidases with bestatin (200 nmol), on the other hand, promoted a potentiation of BRR response. When administered together with bestatin (200 nmol), the suppressive effect of NT (15 nmol) on the BRR response was further enhanced, as was the augmentative action of (D-Trp11)-NT (4 nmol). Upon microinjection into the bilateral nucleus tractus solitarius (NTS), NT (600 pmol) and (D-Trp11)-NT (150 pmol) respectively elicited a reduction and enhancement of the BRR response. These results suggest that neurons that contain NT may participate in central cardiovascular regulation by tonically suppressing the BRR, possibly via an action on the NTS where baroreceptor afferents terminate.